Search

Your search keyword '"Marc, Debled"' showing total 62 results

Search Constraints

Start Over You searched for: Author "Marc, Debled" Remove constraint Author: "Marc, Debled" Publisher elsevier bv Remove constraint Publisher: elsevier bv
62 results on '"Marc, Debled"'

Search Results

1. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study

Catalog

Books, media, physical & digital resources

3. 314P Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane

4. 231P Prognosis and efficacy of frontline treatment for HR+ HER2- metastatic breast cancer occurring in gBRCA1/2 carriers

5. Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in patients with thoracic or extra-thoracic malignancies

6. Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

7. LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

8. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)

9. 279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016

10. Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’

11. 102P Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database

12. Facteurs pronostiques de la survie sans progression chez les patientes atteintes d’un cancer du sein métastatique de type RH+/HER2- avant l’avènement des inhibiteurs CDK dans la cohorte nationale ESME

13. 280MO Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study

14. 306P Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program

15. 281MO Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database

16. Oncofertility and breast cancer: Where have we come from, where are we going?

17. Utiliser une signature moléculaire pour la prise en charge d'une patiente atteinte d'un cancer du sein : la quête du Graal…

18. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude

19. La connaissance du statut de BRCA1 devrait-elle avoir un impact sur le choix d’un cytotoxique dans le cancer du sein ? Revue de la littérature

20. Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making

21. Le cancer du sein triple-négatif. Le triple-négatif est fréquent chez les patientes mutées : comment ne pas le rater ? Comment le caractériser ? De manière plus générale, l’imagerie peut-elle orienter vers le diagnostic histologique ?

22. 5-years RFS and prognostic factors study in HR-positive HER2-negative breast cancer patients treated with neoadjuvant endocrine therapy : Pooled analysis of two phase II trials

23. Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

24. Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the HER2-positive subgroup

25. Diagnostic du cancer du sein après 74 ans : information donnée par les structures de gestion du dépistage organisé à la sortie de la tranche d’âge concernée

26. Radiological features of triple-negative breast cancers (73 cases)

27. Aspects radiologiques des cancers du sein triple négatifs : à propos de 73 cas

28. Le sein inflammatoire : conduite à tenir, algorithmes décisionnels, principes thérapeutiques

29. The inflammatory breast: Management, decision-making algorithms, therapeutic principles

30. FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis

31. Chemotherapy treatment for older women with metastatic breast cancer: What is the evidence?

32. Traitements médicaux des cancers du sein RH+ Her2−

33. Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort

34. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME MBC COHORT

35. Marqueurs biologiques de résistance à l'hormonothérapie dans les cancers du sein

36. Outcomes of 9800 metastatic luminal HER2-negative breast cancer patients in the French national real-life UNICANCER ESME-breast cohort

37. 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials

38. D2-40 in breast cancer: should we detect more vascular emboli?

39. Carcinomes canalaires in situ bilatéraux: événements indépendants ou maladie bilatérale?

40. When will more useful predictive factors be ready for use?

41. Erratum à l’article : « Dépistage du cancer du sein : en route vers le futur » [Bull. Cancer 103 (2016) 753–763]

42. Hypocalcemia Following Pamidronate Administration for Bone Metastases of Solid Tumor

43. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study

44. Follicular lymphomas — a review of treatment modalities

45. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up

46. Cancers du sein localement avancés : facteurs prédictifs de mastectomie après chimiothérapie néoadjuvante

47. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)

48. PO56 BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTOR–POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HER2–) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC)

49. Predictors of Hypertension in Ibcsg 18-98 / Big 1-98: Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-Positive, Early Breast Cancer

50. Doxorubin-based adjuvant chemotherapy for elderly patients with hormone receptors negative breast carcinoma: a French geriatric oncology group (GERICO) phase II multicentric program